Skip to content

United Therapeutics

US · UTHR #836 by market cap Listed 1970
545.00 +3.38 +0.62%
Live - 5344 symbols - heartbeat 61s ago · 2026-10-08 06:19
Pre-market 546.17 +0.21%
After-hours 545.00 0.00%
Overnight 546.00 +0.18%
Market cap
23.38B
P/B
3.65
EPS
27.86
Reader sentiment Are you bullish or bearish on UTHR?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    J.P. Morgan Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $687
    Market Newswire · 2026/7/23
  • Rating change
    Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $714
    Market Newswire · 2026/7/10
  • Rating change
    BofA Securities Maintains United Therapeutics(UTHR.US) With Hold Rating, Cuts Target Price to $613
    Market Newswire · 2026/7/10
  • Rating change
    Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $700
    Market Newswire · 2026/6/12
  • United Therapeutics(UTHR.US) Officer Sells US$4.52 Million in Common Stock
    Market Newswire · 2026/9/29
  • Rating change
    Jefferies Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $704
    Market Newswire · 2026/9/9
  • Rating change
    RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $677
    Market Newswire · 2026/8/6
  • Rating change
    Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $700
    Market Newswire · 2026/9/2
  • RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $677
    Market Newswire · 2026/10/1
  • Rating change
    Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $738
    Market Newswire · 2026/7/31
  • Rating change
    Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating
    Market Newswire · 2026/6/29
  • United Therapeutics(UTHR.US) Officer Sells US$4.54 Million in Common Stock
    Market Newswire · 2026/10/1
  • Rating change
    J.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)
    TipRanks · 2026/5/20
  • United Therapeutics(UTHR.US) Officer Sells US$4.57 Million in Common Stock
    Market Newswire · 2026/9/30
  • Rating change
    H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $660
    Market Newswire · 2026/8/7
  • Rating change
    RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $704
    Market Newswire · 2026/7/9
  • Rating change
    TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $675
    Market Newswire · 2026/9/2
  • Rating change
    Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Cuts Target Price to $700
    Market Newswire · 2026/8/6
  • United Therapeutics(UTHR.US) Officer Sells US$4.5 Million in Common Stock
    Market Newswire · 2026/9/26
  • Rating change
    Goldman Sachs Initiates United Therapeutics(UTHR.US) With Sell Rating, Announces Target Price $321
    Market Newswire · 2026/9/25

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 06:19:20 · For reference only, not investment advice and not tailored to your situation.